Eva Florensa Zanuy

  • florensae@unican.es
  • 942 206 799 ext. 25917
  • Neurobiological Basis of the Mechanism of Action of Drugs acting at the Central Nervous System
  • Neuropharmacology
  • Department of Cell & Molecular Signalling

​She studied the Biomedical Sciences bachelor's degree in Universitat de Lleida, and during this period she realized different laboratory stays (Biochemical department of the Clinic Analysis laboratory of HUAV, Cell signaling and apoptosis group and Yeast signaling group in IRB Lleida, Research in the function of T lymphocytes in tumoral suppression and autoimmunity in CNB Madrid). When she finished, she received a summer AECC grant and worked in the group "Clinic and experimental research in digestive and oncohematologic diseases" in IRB Lleida. Afterwards, she studied the Master's degree "Initiation to research in mental health" in UAB, performing her laboratory practice in the group "Neurobiological basis of the mechanism of action of drugs acting at the central nervous system" in IBBTEC, where she is now performing her PhD thesis about the antidepressant properties of Cannabidiol and its mechanism of action. During her PhD, she has done a research stay in Prof. John Cryan's group in the APC Microbiome Ireland Institute, taking part in a project about the microbiota-gut-brain axis.  

Neurobiological Basis of the Mechanism of Action of Drugs acting at the Central Nervous System


Research lines 

The main research line of the group deals with the neurochemical and neuroplastic signals involved in the pathogeny of neuropsychiatric diseases (major depression, schizophrenia) and, associated to that,  in the mechanism of action of antidepressant and antipsychotic  drugs. The goals of our neuropharmacological research include the study of: 
    • The role of monoaminergic systems (manly serotonin, 5-HT) in these psychiatric diseases and their modulation by chronic administration of antidepressants, with special interest on 5-HT1 and 5-HT4 receptors
    • The identification of brain  neuroplastic and neurogenetic pathways that could be targets of new pharmacological strategies for the treatment of depression and schizophrenia (b-catenin, BDNF)
    • The relationship between central aminergic pathways and recently identified neuromodulator systems (endocannabinoid, mTOR) and its relevance n major depression

For this purpose, studies in laboratory animals, models of depression and psychosis, and in blood and postmortem samples from depressed and schizophrenic patients are carried out. Behavioural, pharmacological (in vivo assays, receptor labeling), cell biology (immunocytochemistry, neurogenesis), biochemical (second messengers, G proteins), electrophysiological (in vivo and slice recordings) and molecular approaches (gen silencing, transfected receptors) are used.

Other sublines of research of the group include: 
    • The neurobiological basis of the analgesic responses induced by antidepressants
    • The identification of the intracellular signaling mechanisms associated to 5-HT receptor subtypes
    • The analysis of polymorphisms for proteins of relevance for the etiopathogeny of depressive disorders 
    • The characterization of animal models of psychiatric disorders

Funding

    • CICYT, Ministerio de Ciencia e Innovación. Cannabidiol como acelerador de la respuesta farmacológica antidepresiva: una vía hacia la identificación de los mecanismos celulares implicados en la depresión (SAF2015-67457-R). Enero 2016-Diciembre 2018.
    • CICYT, Ministerio de Ciencia e Innovación. Fármacos antidepresivos y dianas de señalización intracelular: implicación de mecanismos de proliferación (SAF07-61862). Octubre 2007-Septiembre 2012
    • Neuroplasticity mechanisms involved in the fast antidepressant response of 5-HT4 receptor agonists: role of the Wnt-b-catenin and mTOR pathways (SAF2011-25020 ). Enero 2012-Diciembre 2014.
    • Instituto de Salud Carlos III. CIBER de Salud Mental, 2009-
    • Programa ZENIT,  Ministerio de Ciencia e Innovación (con BrainCo y FaesFarma SA).Nuevas aproximaciones en el tratamiento de las enfermedades del sistema nervioso. Enero 2010-Diciembre 2012


Ángel Pazos Carro (IP)

View more

Álvaro Díaz Martínez

View more

Elena Castro Fernández

View more

Daniel Coca De Pablo

View more

Mª Fuencisla Pilar Cuéllar

View more

Júlia Senserrich Guerrero

View more